Edition:
United Kingdom

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

17.02USD
26 Apr 2018
Change (% chg)

$0.80 (+4.93%)
Prev Close
$16.22
Open
$16.33
Day's High
$17.28
Day's Low
$16.30
Volume
574,302
Avg. Vol
707,734
52-wk High
$18.93
52-wk Low
$5.22

Chart for

About

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $1,461.92
Shares Outstanding(Mil.): 125.38
Dividend: --
Yield (%): --

Financials

  IMMU.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.44 -- --
ROI: -367.82 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Immunomedics Q2 Loss Per Share $0.02

* IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE

08 Feb 2018

BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer

* IMMUNOMEDICS ANNOUNCES AGREEMENT WITH UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER TO EXPAND SACITUZUMAB GOVITECAN (IMMU-132) INTO PROSTATE CANCER

11 Jan 2018

BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln

* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION

08 Jan 2018

BRIEF-Immunomedics appoints Michael Pehl president and CEO

* Immunomedics appoints Michael Pehl president and chief executive officer to lead next phase of transformative growth

09 Nov 2017

BRIEF-Immunomedics announces first quarter fiscal results

* Immunomedics announces first quarter fiscal 2018 results and provides corporate update

09 Nov 2017

Competitors

Earnings vs. Estimates